Fab Biopharma

🔬Early Success in Targeting Autoimmune Disorders 🔬 At Fab Biopharma, we’re seeing promising early outcomes with our bispecific soluble receptors in preclinical studies. Our ability to leverage natural receptor-ligand dynamics and fine-tune binding affinities allows us to create therapies that deliver precise, effective modulation of immune activity without triggering unwanted side effects. These receptors are not only safer, but they also show superior binding efficiency compared to traditional monoclonal antibodies, positioning us to make significant strides in the treatment of lupus and Sjögren’s. Learn more about our development process in this latest article: https://lnkd.in/eG8BgmbN #DrugDevelopment #WomensHealth #BiopharmaInnovation #LifeSciences

⚙️ Harnessing the Power of Bispecific Soluble Receptors⚙️ Fab Biopharma’s bispecific soluble receptors stand out not only for their therapeutic potential but also for their manufacturing efficiency. By requiring only a single gene for expression — compared to the four needed for bispecific antibodies — we streamline production and ensure greater stability during scale-up. This innovative approach reduces complexity, accelerates development timelines, and enhances the therapeutic profile of our treatments. Read more about the potential of bispecific soluble receptors in our latest article: https://lnkd.in/eG8BgmbN   #DrugDevelopment #WomensHealth #BiopharmaInnovation #LifeSciences

🌍 Transforming the Future of Women's Health 🌍 In our latest thought leadership piece, Fab Biopharma is taking a bold stand to address the unmet needs in women's health. Co-authors Bill Freimuth and Chia Chia Sun share how our research is focused on developing biologics that specifically target female health issues, from autoimmune diseases to osteoporosis. Don't miss this compelling article highlighting our mission to ensure women receive the care they need. Check it out here: https://lnkd.in/eu8g9pPk #DrugDevelopment #WomensHealth #BiopharmaInnovation #LifeSciences

🌟 New Article Alert: Revolutionizing Autoimmune Disease Management with Soluble Bispecific Receptors🌟 Fab Biopharma is pioneering bispecific soluble receptor therapies to address complex autoimmune diseases like Sjögren’s and lupus. These innovative molecules engage both T and B cells while avoiding the cross-linking risks of traditional bispecific antibodies, offering a more precise, targeted approach. In our newest article authored by Fab Biopharma Co-Founders Reiner Gentz, Ph.D and Gardiner Smith, J.D, discover how our receptors are designed to modulate, not suppress, immune responses — a critical advancement for diseases where immune function must be carefully balanced. Read the full article here: https://lnkd.in/eG8BgmbN #DrugDevelopment #WomensHealth #BiopharmaInnovation #LifeSciences

🔬 Advancing Women’s Health Through Innovation 🔬 At Fab Biopharma, we're challenging the status quo in drug development. Our newest article, authored by Bill Freimuth and Chia Chia Sun, explores how our female-centric approach is reshaping the biopharma landscape. By focusing on female physiology and real-life needs, we're driving innovation to close the gender gap in healthcare. Learn more about our commitment to revolutionizing women’s health. Discover the article: https://lnkd.in/eu8g9pPk   #DrugDevelopment #WomensHealth #BiopharmaInnovation #LifeSciences

🌟 New Article Alert! 🌟 Fab Biopharma is leading the charge to transform drug development with a focus on women's health. Our latest article, co-authored by Bill Freimuth and Chia Chia Sun, delves into the critical need for gender-inclusive research and how Fab Biopharma is pioneering innovative approaches to address women's unique health issues. Discover the groundbreaking work we’re doing to ensure women receive the targeted treatments we deserve. Read the full article here: https://lnkd.in/eu8g9pPk #DrugDevelopment #WomensHealth #BiopharmaInnovation #LifeSciences

Applying our expertise to a global need. Fab Biopharma has detailed operational knowledge for generating preclinical data which will support IND submissions for initiation of clinical studies on bispecific receptor fusion drugs in separate disease indications. Learn more: https://lnkd.in/eWCVEuwg #DrugDiscovery #LifeSciences #AutoimmuneDisease #WomensHealth

Revolutionizing Biologics (and Biology) through a Focus on Women. In this Q&A, Chia Chia Sun and Gardiner Smith, two of Fab Biopharma’s founders, discuss the company’s vision and mission and the unique expertise the team brings to drive their novel approach, with Pharma's Almanac Editor in Chief David Alvaro, Ph.D. Read the article here: https://lnkd.in/em8aUq7f #DrugDiscovery #LifeSciences #AutoimmuneDisease #WomensHealth

Fab Biopharma is taking on Pervasive, Debilitating Autoimmune Disorders. Differences in female biology impact drug development, driving us to innovate in drug science through R&D that takes a female-centered perspective. Our goal is to reduce sex-based scientific bias including in formative cellular biology studies and landmark clinical trials. Learn more: https://lnkd.in/eWCVEuwg #DrugDiscovery #LifeSciences #AutoimmuneDisease #WomensHealth

Fab Biopharma’s leadership team has a tremendous track record of success, in drug discovery and development, clinical development, commercial strategy, and intellectual property. Meet the rest of the Fab Biopharma team leveraging female biology to drive innovation in drug development: https://lnkd.in/eWCVEuwg Bill Freimuth | Chia Chia Sun | Gardiner Smith | Reiner Gentz #DrugDiscovery #LifeSciences #AutoimmuneDisease #WomensHealth